Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its trivalent influenza virus split vaccine (MDCK cells). This vaccine is designed for the prevention of influenza caused by vaccine-related influenza viruses in individuals aged six months and above.
In China, the influenza vaccines available include both trivalent and quadrivalent options, with trivalent vaccines primarily targeting the H1N1 and H3N2 subtypes of influenza A, as well as the Victoria lineage of influenza B. Olymvax Bio’s product marks the first of its kind to be filed for clinical use in the country. Cell matrix influenza vaccines, like the one developed by Olymvax Bio, offer the potential for higher production yields, more stable product quality, and lower production costs through large-scale bioreactor cultivation. Currently, no cell-based influenza vaccines are available on the market in China, despite foreign manufacturers such as CSL having already launched their own cell matrix influenza vaccines.
The clinical study approval for Olymvax Bio’s trivalent influenza vaccine highlights the company’s commitment to advancing vaccine technology and addressing public health needs in China.- Flcube.com
